1. Home
  2. SBFG vs AGEN Comparison

SBFG vs AGEN Comparison

Compare SBFG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$23.25

Market Cap

136.9M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.06

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
AGEN
Founded
1983
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.9M
147.4M
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
SBFG
AGEN
Price
$23.25
$3.06
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
24.3K
591.3K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
2.98%
N/A
EPS Growth
27.33
100.00
EPS
0.69
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$33.96
$2.82
Revenue Growth
N/A
89.95
52 Week Low
$18.05
$2.71
52 Week High
$25.05
$7.34

Technical Indicators

Market Signals
Indicator
SBFG
AGEN
Relative Strength Index (RSI) 61.76 44.19
Support Level $20.94 $2.93
Resistance Level $23.93 $3.15
Average True Range (ATR) 0.89 0.21
MACD 0.10 -0.00
Stochastic Oscillator 57.03 31.67

Price Performance

Historical Comparison
SBFG
AGEN

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: